Clinical Trials
4 trialsNCT06051409 2026-04-30
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT07152041 2025-09-03
CAMS-Ph+ B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Recruiting
NCT06423911 2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT05311943 2022-07-29
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
Shenzhen Second People's Hospital
Phase 3 Unknown